In addition to hypoglycemic effects, these medications appear to offer some reduction in major adverse cardiac event (MACE) occurrence [21]
Yes, we offer peptide therapy at our clinic
Mounjaro (tirzepatide) injection, for subcutaneous use, Food and Drug Administration (2026) FDA approves Lillys Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with Type 2 diabetes, Eli Lilly (2022) Mounjaro (tirzepatide) Injection: The first and only GIP and GLP-1 receptor agonist approved for Type 2 Diabetes, Eli Lilly Declaratory order: Resolution of shortages of tirzepatide injection products (Mounjaro and Zepbound), Food and Drug Administration (2024) FDAs concerns with unapproved GLP-1 drugs used for weight loss, Food and Drug Administration (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
David Garcia, DO, founder of Polaris Rejuvenation
In fact, the FDA designated BPC-157 as a Category 2 bulk drug substance, meaning it cannot be compounded by commercial pharmaceutical companies due to insufficient safety evidence in humans
Below you can jump directly to the section that best fits your needs